Ulcerative Colitis Clinical Trial
Official title:
A Phase I Study of Fecal Microbiota Transplantation (FMT) in Immunomodulator Dependent Pediatric Ulcerative Colitis (UC)
Patients diagnosed with ulcerative colitis (UC), a specific type of inflammatory bowel
disease, will be invited to take part in this study. The investigators do not know what
causes UC. However, the microbes (such as bacteria and viruses), which normally live in our
intestines are thought to play an important role in the development of UC. There are many
treatment options for UC such as steroids,and other medications that decrease inflammation.
However, none of these can cure the disease.
This study aims to treat pediatric UC in an alternative fashion by changing the microbes in
the gut by giving the participant's stool specimens from healthy adult individuals. There is
some evidence from a few cases of adult UC that this therapy may cure the disease or at
least provide long lasting suppression (remission) of the symptoms. The investigators would
like to test this therapeutic intervention in children with UC.
The purpose of this study is to (1) examine the microbiome of stool and colon (2) and to
determine whether healthy-donated stool enemas can treat pediatric ulcerative colitis. (3)
The investigators will also study the effects of the treatment on colonic gene expression.
FMT RECIPIENTS:
Participants will be recruited from the patient population treated by the Pediatric
Gastroenterology, Hepatology, and Nutrition Section at Baylor College of Medicine/Texas
Children's Hospital.
I. Activities prior to starting FMT therapy:
1. Participants will be asked to discontinue or taper their current home medications for
ulcerative colitis.
2. Participants will be asked to complete enema training.
3. The participant and family will be counseled in case emergency surgical and/or
intensive care interventions are required.
4. Survey Completion to assess clinical symptoms.
II. Initiation of FMT Therapy:
1. Pre-colonoscopy and FMT therapy preparation:
One to two days prior to scheduled colonoscopy the study participant will be asked to
provide a stool sample. They will also undergo a bowel clean-out with Miralax for
colonoscopy preparation. Colonoscopy (endoscopic examination of the large bowel) will
be used to deliver the first donor fecal transplant at the beginning of the therapeutic
protocol.
2. FMT treatment and Initial colonoscopy:
Fecal microbiota transplantation is made possible by utilizing a donor (healthy adult)
providing their stool sample. The donor's stool will be screened and tested for known
disease-causing agents including viruses, bacteria and parasites to prevent spread of
disease to the participant.
On the first day of treatment, the participant will undergo a colonoscopy to deliver the
filtered donor stool directly into their colon. Additionally, biopsies will be taken during
this procedure for routine diagnostic as well as research purposes.
III. Subsequent FMT treatments:
Enemas will be given periodically to complete a total of 1-year therapy.
IV. Follow-up endoscopy and samples:
A similar but more limited procedure (sigmoidoscopy) will be repeated at 14 weeks into the
study period. Biopsies will be taken during this procedure for routine diagnostic as well as
research purposes.
FMT DONORS:
Potential healthy adult stool donors (between 18 and 45 years of age) will be recruited by
the research staff. They will be asked to volunteer for the screening and regularly supply
stool samples according to the study protocol.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |